Literature DB >> 16212410

Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance.

Zongming Fu1, Catherine Fenselau.   

Abstract

One-hundred twenty-four proteins have been identified in the soluble nuclear protein mixture from MCF-7 human breast cancer cells, of which more than 90% are classically categorized as nuclear proteins. Proteins were also studied from three drug resistant MDF-7 lines, selected previously from the same parent line by exposure to etoposide, to mitoxantrone, or to adriamycin in the presence of verapamil. Both quantitative gel comparisons and stable isotope labeling were used to identify a total of fourteen proteins whose abundances are altered by more than 2-fold in the three resistant lines. Several cytoskeleton proteins, cytokeratin 8, cytokeratin 19, septin 2, and alpha tropomyosin, are decreased in common across the three resistant cell lines. PARP-l (poly[ADP-ribosyl]transefrase or connexion) is found to be less abundant in all three resistant lines. Nucleolin is more abundant in lines resistant to etoposide and mitoxantrone, while the mitotic checkpoint protein BUB 3 is more abundant in the line resistant to adriamycin/verapamil.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212410     DOI: 10.1021/pr0501158

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

Review 1.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

2.  The histone variant MacroH2A1 regulates target gene expression in part by recruiting the transcriptional coregulator PELP1.

Authors:  Kristine M Hussey; Hongshan Chen; Christine Yang; Eugene Park; Nasun Hah; Hediye Erdjument-Bromage; Paul Tempst; Matthew J Gamble; W Lee Kraus
Journal:  Mol Cell Biol       Date:  2014-04-21       Impact factor: 4.272

Review 3.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

4.  Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

Authors:  Pawel Domagala; Tomasz Huzarski; Jan Lubinski; Karol Gugala; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2010-10-13       Impact factor: 4.064

5.  Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.

Authors:  Ling Yao; Yan Zhang; Keying Chen; Xiaofang Hu; Lisa X Xu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

6.  Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway.

Authors:  Jing Ke; Chunming Gu; Heyan Zhang; Yang Liu; Wenhao Zhang; Huiling Rao; Shan Li; Fuyun Wu
Journal:  J Oncol       Date:  2021-04-21       Impact factor: 4.375

7.  Proteome characterization of a human urothelial cell line resistant to the bladder carcinogen 4-aminobiphenyl.

Authors:  Roberta Pastorelli; Federica Saletta; Donatella Carpi; Roberta Campagna; Carlo dell'Osta; Silvia Schiarea; Paolo Vineis; Luisa Airoldi; Giuseppe Matullo
Journal:  Proteome Sci       Date:  2007-05-03       Impact factor: 2.480

8.  Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.

Authors:  Damien Destouches; Diala El Khoury; Yamina Hamma-Kourbali; Bernard Krust; Patricia Albanese; Panagiotis Katsoris; Gilles Guichard; Jean Paul Briand; José Courty; Ara G Hovanessian
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.